The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Impairment of dendritic cells (DC), the most effective activators of anticancer immune responses, is one mechanism for defective antitumor immunity, but the causes of DC impairment are incompletely understood. We evaluated the association of impaired DC differentiation with angiogenesis-associated molecules D-dimer, vascular endothelial growth factor (VEGF), urokinase plasminogen activator (uPA), and plasminogen activator inhibitor (PAI-1) in peripheral blood from 41 patients with lung, breast, and colorectal carcinoma. Subsequently, we studied the effect of administration of the anti-VEGF antibody (bevacizumab) on DC maturation and function in vivo. Compared with healthy volunteers, cancer patients had a bias toward the immunoregulatory DC2, had deficits in DC maturation after overnight in vitro culture, and had a significant increase in immature myeloid cell progenitors of DC (0.50 +/- 0.31% vs. 0.32 +/- 0.16% of peripheral blood mononuclear cells, respectively, P = 0.011). A positive correlation was found between the percentage of DC2 and PAI-1 (R = 0.50) and between immature myeloid cells and VEGF (R = 0.52). Bevacizumab administration to cancer patients was associated with a decrease in the accumulation of immature progenitor cells (0.39 +/- 0.30% vs. 0.27 +/- 0.24%, P = 0.012) and induced a modest increase in the DC population in peripheral blood (0.47 +/- 0.23% vs. 0.53 +/- 0.30%). Moreover, anti-VEGF antibody treatment enhanced allo-stimulatory capacity of DC and T cell proliferation against recall antigens. These data suggest that DC differentiation is negatively associated with VEGF levels and may be one explanation for impaired anticancer immunity, especially in patients with advanced malignancies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“improved DC maturation”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Osada et al., 2008
Citations
Cites
Peichev, M., Naiyer, A. J., Pereira, D., Zhu, Z., Lane, W. J., Williams, M., Oz, M. C., Hicklin, D. J., Witte, L., Moore, M. A. S., et al. (2000) · Blood · doi:10.1182/blood.v95.3.952.003k27_952_958 · Cited by 2,277 · cited 1×
“CECs were deWned as CD45¡/Flk+/CD15¡ and CEPs as CD45¡/Flk+/CD133+ [21, 22].”
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977 · cited 3×
“Furthermore, high VEGF levels appear to block DC diVerentiation from immature precursors [16].”
Dhodapkar, M. V., Steinman, R. M., Krasovsky, J., Munz, C., & Bhardwaj, N. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.2.233 · Cited by 1,359 · cited 1×
“One mechanism for doing so is the inhibition of DC function [ 5 ].”
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337 · cited 2×
“Because Gabrilovich and colleagues [10, 11] showed that the undiVerentiated hematopoietic cells from cancer patients inhibited the function of fully diVerentiated DC, we hypothesized that administration of anti-VEGF Ab”
Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., & Carbone, D. P. (1998) · Blood · doi:10.1182/blood.v92.11.4150 · Cited by 1,048 · cited 1×
“studies performed by Gabrilovich, Carbone, and colleagues [10, 28, 29], the presence of increased iMC in cancer patients, which is associated with elevated levels of VEGF, was demonstrated to be involved in mediating DC dysfunction.”
Regulation of angiogenesis via vascular endothelial growth factor receptors.
Veikkola, T., Karkkainen, M. J., Claesson, L., & Alitalo, K. K. (2000) · PubMed · Cited by 864
SERAFINI, P., BORRELLO, I., & BRONTE, V (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.07.005 · Cited by 762
Clinical significance of defective dendritic cell differentiation in cancer.
Almand, B., Resser, J. R., Lindman, B. R., Nadaf, S., Clark, J. I., Kwon, E. D., Carbone, D. P., & Gabrilovich, D. I. (2000) · PubMed · Cited by 699
Look, M. P., van Putten, W. L. J., Duffy, M. J., Harbeck, N., Christensen, I. J., Thomssen, C., Kates, R., Spyratos, F., Ferno, M., Eppenberger-Castori, S., et al. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.2.116 · Cited by 596 · cited 1×
“Since PAI-1 is associated with poor prognosis of patients with diVerent types of cancers [24, 25, 30], PAI-1 may have indirect correlation with immunoregulatory DC (DC2).”
The multifaceted circulating endothelial cell in cancer: towards marker and target identification
Bertolini, F., Shaked, Y., Mancuso, P., & Kerbel, R. S. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1971 · Cited by 575 · cited 1×
“CECs were deWned as CD45¡/Flk+/CD15¡ and CEPs as CD45¡/Flk+/CD133+ [21, 22].”
Cited by
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,490
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376
McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0053-3 · Cited by 1,260
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Gotwals, P., Cameron, S., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., Mueller, B., Quaratino, S., Sabatos-Peyton, C., Petruzzelli, L., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.17 · Cited by 953
Shrimali, R. K., Yu, Z., Theoret, M. R., Chinnasamy, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0153 · Cited by 677
The secret ally: immunostimulation by anticancer drugs
Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 670
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Khan, K. A., & Kerbel, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.9 · Cited by 657
Targeting VEGF/VEGFR to modulate antitumor immunity
Yang, J., Yan, J., & Liu, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00978 · Cited by 646
“Bevacizumab was found to increase the number of DCs in peripheral blood of cancer patients and enhance the allostimulatory capacity of DCs against recall antigens (90).”
BackgroundDefining the role of the tumor vasculature in antitumor immunity and immunotherapy
Schaaf, M. B., Garg, A. D., & Agostinis, P. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0061-0 · Cited by 629
Secretion of immunoregulatory cytokines by mesenchymal stem cells
Kyurkchiev, D. (2014) · World Journal of Stem Cells · doi:10.4252/wjsc.v6.i5.552 · Cited by 617
Deciphering and Reversing Tumor Immune Suppression
Motz, G. T., & Coukos, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.005 · Cited by 598
“Finally, Tregs can engage in crosstalk with DCs, inducing the expression of IDO, IL-10, and TGFβ expression from DCs through direct interactions (Facciabene et al., 2012).”
InfluentialBevacizumab plus ipilimumab in patients with metastatic melanoma
Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., Zeng, W., Giobbie-Hurder, A., Atkins, M. B., Ibrahim, N., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0053 · Cited by 593
“In patients with colorectal cancer, bevacizumab improved the antigen-presenting capacity of circulating dendritic cells (29).”
Schmittnaegel, M., Rigamonti, N., Kadioglu, E., Cassará, A., Wyser Rmili, C., Kiialainen, A., Kienast, Y., Mueller, H.-J., Ooi, C.-H., Laoui, D., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9670 · Cited by 582
“The administration of bevacizumab to cancer patients increased the allostimulatory capacity and proliferation of DCs and T cells, respectively, in response to recall antigens ex vivo (48).”
BackgroundClinical management of metastatic colorectal cancer in the era of precision medicine
Ciardiello, F., Ciardiello, D., Martini, G., Napolitano, S., Tabernero, J., & Cervantes, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21728 · Cited by 528
Dendritic Cells and Their Role in Immunotherapy
Gardner, A., de Mingo Pulido, Á., & Ruffell, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00924 · Cited by 485
“inhibition has also been shown to enhance DC maturation in human patients (104), suggesting that this may contribute to the efficacy of VEGF inhibitors in the clinical setting.”
BackgroundThe Intersection between Tumor Angiogenesis and Immune Suppression
Rahma, O. E., & Hodi, F. S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1543 · Cited by 472
Beyond immune checkpoint blockade: emerging immunological strategies
Kubli, S. P., Berger, T., Araujo, D. V., Siu, L. L., & Mak, T. W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00155-y · Cited by 461
Noman, M. Z., Hasmim, M., Messai, Y., Terry, S., Kieda, C., Janji, B., & Chouaib, S. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00207.2015 · Cited by 400
“Moreover, anti-VEGF therapy was associated with a decrease in immature myeloid cells and DCs in patients (85).”
BackgroundLessons learned from the blockade of immune checkpoints in cancer immunotherapy
Li, X., Shao, C., Shi, Y., & Han, W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0578-4 · Cited by 381
“Additionally, treatment with bevacizumab has been associated with enhanced tumor antigen presentation in patients with lung, breast, and colorectal cancers [187].”
BackgroundPI3K-AKT-mTOR inhibition in cancer immunotherapy, redux
O’Donnell, J. S., Massi, D., Teng, M. W. L., & Mandala, M. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.04.015 · Cited by 375
Targeting the tumor vasculature to enhance T cell activity
Lanitis, E., Irving, M., & Coukos, G. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.011 · Cited by 338
Control of the Immune Response by Pro-Angiogenic Factors
Voron, T., Marcheteau, E., Pernot, S., Colussi, O., Tartour, E., Taieb, J., & Terme, M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00070 · Cited by 325
“Osada has then confirmed this result in humans by demonstrating an increase in the number of DCs in peripheral blood and an improvement of DCs functions in advanced solid cancer patients treated with bevacizumab (anti-VEGF-A) (72).”
Tartour, E., Pere, H., Maillere, B., Terme, M., Merillon, N., Taieb, J., Sandoval, F., Quintin-Colonna, F., Lacerda, K., Karadimou, A., et al. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9281-4 · Cited by 316
Dendritic cells as shepherds of T cell immunity in cancer
Pittet, M. J., Di Pilato, M., Garris, C., & Mempel, T. R. (2023) · Immunity · doi:10.1016/j.immuni.2023.08.014 · Cited by 313
Hack, S. P., Zhu, A. X., & Wang, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.598877 · Cited by 286
“org 5 number of mature DCs in peripheral blood of cancer patients (67).”
BackgroundTargeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
Hughes, P. E., Caenepeel, S., & Wu, L. C. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.04.010 · Cited by 282
“In addition, treatment of patients with colorectal, lung, or breast cancer with bevacizumab was associated with reductions in immature dendritic cells and improved dendritic cell antigen presentation [82].”
BackgroundOtt, P. A., Hodi, F. S., & Buchbinder, E. I. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00202 · Cited by 242
“Inhibition of VEGF with bevacizumab leads to a decrease in immature progenitor cells and a modest increase in the DC population in the peripheral blood of cancer patients (37).”
BackgroundZhao, Y., Guo, S., Deng, J., Shen, J., Du, F., Wu, X., Chen, Y., Li, M., Chen, M., Li, X., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.70958 · Cited by 246
“Bevacizumab can affect the maturation and function of DCs in vivo by slightly increasing DC numbers and significantly reducing immature myeloid cell numbers [82].”
BackgroundAnti-Angiogenics: Current Situation and Future Perspectives
Zirlik, K., & Duyster, J. (2018) · Oncology Research and Treatment · doi:10.1159/000488087 · Cited by 216
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Combinations of Bevacizumab With Cancer Immunotherapy
Chen, D. S., & Hurwitz, H. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000327 · Cited by 207
Self-citationSugawara, S., Lee, J.-S., Kang, J.-H., Kim, H. R., Inui, N., Hida, T., Lee, K. H., Yoshida, T., Tanaka, H., Yang, C.-T., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.004 · Cited by 193
Mechanisms of Hypoxia-Mediated Immune Escape in Cancer
Barsoum, I. B., Koti, M., Siemens, D. R., & Graham, C. H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2598 · Cited by 201
Immunomodulatory Activity of VEGF in Cancer
(2017) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2016.09.007 · Cited by 194
Hahn, N. M., Stadler, W. M., Zon, R. T., Waterhouse, D., Picus, J., Nattam, S., Johnson, C. S., Perkins, S. M., Waddell, M. J., & Sweeney, C. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6067 · Cited by 190
New strategies for targeting the hypoxic tumour microenvironment in breast cancer
Ward, C., Langdon, S. P., Mullen, P., Harris, A. L., Harrison, D. J., Supuran, C. T., & Kunkler, I. H. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.08.004 · Cited by 181
The pro-tumorigenic host response to cancer therapies
Shaked, Y. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0209-6 · Cited by 181
Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape
Chouaib, S., Messai, Y., Couve, S., Escudier, B., Hasmim, M., & Noman, M. Z. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00021 · Cited by 180
“Moreover, antiVEGF therapy was associated with a decrease in immature myeloid and dendritic cells in patients (Osada et al., 2008).”
BackgroundAt the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
Otano, I., Ucero, A. C., Zugazagoitia, J., & Paz-Ares, L. G. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00718-x · Cited by 184
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 160
Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer
Graziani, G., Tentori, L., & Navarra, P. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2011.09.002 · Cited by 164
Rationally Combining Anti-VEGF Therapy with Checkpoint Inhibitors in Hepatocellular Carcinoma
Hato, T., Zhu, A. X., & Duda, D. G. (2016) · Immunotherapy · doi:10.2217/imt.15.126 · Cited by 161
Improving cancer immunotherapy by targeting tumor-induced immune suppression
Stewart, T. J., & Smyth, M. J. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9280-5 · Cited by 163
“A decrease in the accumulation of immature progenitor cells and an increase in peripheral DCs have also been noted in cancer patients treated with bevacizumab [92].”
Advancements in combining targeted therapy and immunotherapy for colorectal cancer
Singh, M., Morris, V. K., Bandey, I. N., Hong, D. S., & Kopetz, S. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.05.001 · Cited by 156
Direct and indirect regulation of the tumor immune microenvironment by VEGF
Zhang, Y., & Brekken, R. A. (2022) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ru0222-082r · Cited by 157
“Bevacizumab VEGF-A Increases the infiltration of proliferating CD8 T cells; reduces Treg recruitment and decreases the proportion of Ki67 Tregs; reduces MDSCs; promotes differentiation of DCs [54][59] [61][62] [80][106]”
Backgroundvan Cruijsen, H., van der Veldt, A. A. M., Vroling, L., Oosterhoff, D., Broxterman, H. J., Scheper, R. J., Giaccone, G., Haanen, J. B. A. G., van den Eertwegh, A. J. M., Boven, E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0656 · Cited by 135
Tumour Tissue Microenvironment Can Inhibit Dendritic Cell Maturation in Colorectal Cancer
Michielsen, A. J., Hogan, A. E., Marry, J., Tosetto, M., Cox, F., Hyland, J. M., Sheahan, K. D., O'Donoghue, D. P., Mulcahy, H. E., Ryan, E. J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027944 · Cited by 131
“properties but can also elicit an inhibitory effect on DC differentiation and maturation, enhancing tumour survival [1,5,6,7,8].”
BackgroundTargeted inhibition of VEGF receptor 2: an update on ramucirumab
Clarke, J. M., & Hurwitz, H. I. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.810717 · Cited by 142
“VEGFA can stimulate monocyte chemotaxis and inhibit dendritic cell maturation [20,66,67].”
BackgroundSelf-citationTyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
Rassy, E., Flippot, R., & Albiges, L. K. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920907504 · Cited by 143
Mettu, N. B., Ou, F.-S., Zemla, T. J., Halfdanarson, T. R., Lenz, H.-J., Breakstone, R. A., Boland, P. M., Crysler, O. V., Wu, C., Nixon, A. B., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.49040 · Cited by 126
Self-citationWang, P.-F., Song, S., Wang, T., Ji, W., Li, S., Liu, N., & Yan, C. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1494113 · Cited by 144
Overman, M. J., Ernstoff, M. S., & Morse, M. A. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200821 · Cited by 130
Self-citationTumor-Altered Dendritic Cell Function: Implications for Anti-Tumor Immunity
Hargadon, K. M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00192 · Cited by 141
“Similarly, administration of the anti-VEGF Ab bevacizumab to patients with lung, breast, and colorectal carcinoma led to a decrease in the frequency of MDSC and enhanced the T cell stimulatory capacity of DC (145).”
BackgroundCorrupt policemen: inflammatory cells promote tumor angiogenesis
Zumsteg, A., & Christofori, G. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32831bed7e · Cited by 121
Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy
Morse, M. A., Höchster, H. S., & Benson, A. B. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0176 · Cited by 140
“VEGF expression negatively correlates with intraepithelial T-cell infiltration, and bevacizumab-based therapy has previously enhanced immune responses in CRC [93, 94].”
BackgroundSelf-citationLin, A., Schildknecht, A., Nguyen, L. T., & Ohashi, P. S. (2009) · Immunology Letters · doi:10.1016/j.imlet.2009.09.003 · Cited by 135
The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic
Ye, W. (2016) · Developmental Cell · doi:10.1016/j.devcel.2016.03.015 · Cited by 129
Joshi, S., & Durden, D. L. (2019) · Journal of Oncology · doi:10.1155/2019/5245034 · Cited by 129
“A small clinical trial involving 19 metastatic, colorectal patients showed that bevacizumab decreased immature MDSCs and improved the stimulatory capacity of DCs isolated from treated patients [123].”
BackgroundShojaei, F., & Ferrara, N. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.09.001 · Cited by 131
Modulation of Immunity by Antiangiogenic Molecules in Cancer
Terme, M., Colussi, O., Marcheteau, E., Tanchot, C., Tartour, É., & Taïeb, J. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/492920 · Cited by 122
“A study performed on solid cancer patients describes a decrease of immature myeloid cells (CD45+lin−HLA-DR−) after one cycle of bevacizumab treatment [18].”
BackgroundInfluentialTargeting the immune microenvironment for ovarian cancer therapy
Blanc‐Durand, F., Xian, L. C. W., & Tan, D. S. P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1328651 · Cited by 123
“Interestingly, bevacizumab has been shown to signi fi cantly increase T-cells and B-cells in fi ltration, enhance DC maturation and block Tregs proliferation in colorectal and breast models (200 – 202).”
BackgroundConvergent inducers and effectors of T cell paralysis in the tumour microenvironment
Hanahan, D., Michielin, O. A., & Pittet, M. J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00761-z · Cited by 120
Güven, D. C., Kavgacı, G., Erul, E., Syed, M. P., Magge, T., Saeed, A., Yalçın, Ş., & Şahin, İ. H. (2024) · The Oncologist · doi:10.1093/oncolo/oyae013 · Cited by 113
Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment
Qu, P., Wang, L., & Lin, P. C. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.10.022 · Cited by 109
“Accordingly, clinical studies demonstrate that the numbers of CD45 + lin−HLA-DR− human MDSCs decrease with a treatment of bevacizumab, a monoclonal antibody directed against VEGF-A, on patients with lung, breast and colorectal cancers [18].”
BackgroundRole of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion
DeVito, N. C., Plebanek, M. P., Theivanthiran, B., & Hanks, B. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02876 · Cited by 100
The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer
Chen, Y., Zheng, X., & Wu, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.792691 · Cited by 116
Federico, A. D., Rizzo, A., Carloni, R., Giglio, A. D., Bruno, R., Ricci, D., & Brandi, G. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2009455 · Cited by 105
“Bevacizumab increased the DC population while reducing the number of immature progenitor cells in the peripheral blood of cancer patients [38].”
BackgroundMDSCs in cancer: Conceiving new prognostic and therapeutic targets
Sanctis, F. D., Solito, S., Ugel, S., Molon, B., Bronte, V., & Marigo, I. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.08.001 · Cited by 111
Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies
Comunanza, V., & Bussolino, F. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00101 · Cited by 111
“In patients with CRC bevacizumab improved the antigen-presenting capacity of circulating dendritic cells (Osada et al., 2008), revealing an additional mechanism for bevacizumab on immune functions in the context of checkpoint blockade.”
BackgroundKandalaft, L. E., Motz, G. T., Busch, J. I., & Coukos, G. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_95 · Cited by 102
Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer
Manzoni, M., Rovati, B., Ronzoni, M., Loupakis, F., Mariucci, S., Ricci, V., Gattoni, E., Salvatore, L., Tinelli, C., Villa, E., et al. (2010) · Oncology · doi:10.1159/000320609 · Cited by 92
“The effect of bevacizumab was evaluated on cancer patients with advanced disease (lung, breast and colorectal carcinoma) and its administration was found to be associated with a decrease in the pool of immature DCs with only a modest increase in the DC population able to recall antigens [”
BackgroundHallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications
Xiao, T., Lee, J., Gauntner, T. D., Velegraki, M., Lathia, J. D., & Li, Z. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00680-z · Cited by 99
Bluth, M. J., Zaba, L. C., Moussai, D., Suárez‐Fariñas, M., Kaporis, H. G., Fan, L., Pierson, K. C., White, T. R., Pitts-Kiefer, A., Fuentes‐Duculan, J., et al. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.96 · Cited by 94
“Angiogenic factors such as plasminogen activator inhibitor 1 (PAI-1) correlated with an increased number of immature DCs and MDSCs in the blood of patients with advanced malignancies (Osada et al., 2008).”
Nitric Oxide Synthase-2-Derived Nitric Oxide Drives Multiple Pathways of Breast Cancer Progression
Basudhar, D., Somasundaram, V., de Oliveira, G. A., Kesarwala, A. H., Heinecke, J. L., Cheng, R. Y. S., Glynn, S. A., Ambs, S., Wink, D. A., & Ridnour, L. A. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6813 · Cited by 100
“Moreover, the VEGF antibody Avastin can reverse VEGF-mediated disruption of dendritic cell maturation and T-cell proliferation, recruitment, and infiltration at the tumor site (95, 97).”
BackgroundImmunosuppressive effects of vascular endothelial growth factor (Review)
Ribatti, D. (2022) · Oncology Letters · doi:10.3892/ol.2022.13489 · Cited by 101
“Bevacizumab also reverses the VEGF‐induced inhibition of monocyte differentiation into dendritic cells (42) and restores peripheral blood dendritic cell numbers in patients with cancer (43).”
BackgroundMyeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
Peranzoni, E., Ingangi, V., Masetto, E., Pinton, L., & Marigo, I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01590 · Cited by 86
de Aguiar, R. B., & de Moraes, J. Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01023 · Cited by 88
Li, S., Chen, J. Y., & Sun, Z. (2021) · 癌症:英文版 · doi:10.1002/cac2.12183 · Cited by 87
“Bevacizumab Multiple tumors in human patients Immature dendritic cells in peripheral blood↓ Dendritic cell population↑ Allostimulatory capacity of dendritic cells↑ T cell proliferation↑ [44]”
BackgroundLiu, J., Deng, W., Chen, L., Li, Y., Wu, L., Ma, S., Zhang, W., Bu, L., & Sun, Z. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22767 · Cited by 84
“This interaction was observed in several studies which use the antiVEGFmAb or tyrosine kinase inhibitor.(41,42) In addition, there aremany anti-angiogenic drugs that not only target VEGF but also regulate other”
MethodFriedman, C. F., Snyder, A., Zhou, Q. C., Carducci, M. A., de Meritens, A. B., Corr, B. R., Fu, S., Hollmann, T. J., Iasonos, A. E., Konner, J. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001126 · Cited by 85
“17 18 18–23 Supporting these findings, in the phase II IMmotion150 study of bevacizumab and atezolizumab in recurrent RCC demonstrated a promising response rate and progression-free survival (PFS) compared with atezolizumab alone.”
Wang, S., Liechty, B., Patel, S. V., Weber, J. S., Hollmann, T. J., Snuderl, M., & Karajannis, M. A. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2788-6 · Cited by 80
Mulligan, J. K., Rosenzweig, S. A., & Young, M. R. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181b91c9c · Cited by 79
“Similarly Osada et al examined of 41 patients with lung, breast or colorectal carcinoma and reveled that antiVEGF antibody therapy enhanced the capacity of dendritic cells to stimulate T cell proliferation against recall antigens.(42) Lastly, studies by Ko et al, demonstrated in patients with metastatic renal cell car…”
BackgroundKamrava, M. R., Bernstein, M. B., Camphausen, K. A., & Hodge, J. W. (2009) · Molecular BioSystems · doi:10.1039/b911313b · Cited by 84
Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma
Ingels, A., Campi, R., Capitanio, U., Amparore, D., Bertolo, R. G., Carbonara, U., Erdem, S., Kara, Ö., Klatte, T., KRIEGMAIR, M. C., et al. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00592-3 · Cited by 82
Bota, D. A., Chung, J., Dandekar, M., Carrillo, J., Kong, X., Fu, B. D., Hsu, F. P. K., Schönthal, A. H., Hofman, F. M., Chen, T. C., et al. (2018) · CNS Oncology · doi:10.2217/cns-2018-0009 · Cited by 79
“As such, using anti-VEGF therapy via administration of bevacizumab to cancer patients can enhance dendritic cell and T-cell responses to antigens [27], and potentially increase the level and specificity of the immunostimulation achieved by ERC1671.”
MethodImmunomodulatory effects of anti-angiogenic drugs
Heine, A., Held, S., Bringmann, A., Holderried, T. A. W., & Brossart, P. (2011) · Leukemia · doi:10.1038/leu.2011.24 · Cited by 79
Old Player-New Tricks: Non Angiogenic Effects of the VEGF/VEGFR Pathway in Cancer
Ntellas, P., Mavroeidis, L., Gκoura, S., Gazouli, I., Amylidi, A.-L., Papadaki, A., Zarkavelis, G., Mauri, D., Karpathiou, G., Kolettas, E., et al. (2020) · Cancers · doi:10.3390/cancers12113145 · Cited by 76
“Bevacizumab has shown promising results in reversing the VEGF-induced inhibition of differentiation of monocytes into DCs in vitro [131], as well as in restoring peripheral blood DC numbers in cancer patients and promoting their activation [127,130].”
BackgroundCancer-Associated Myeloid Regulatory Cells
Vlaeminck, Y. D., González-Rascón, A. A., Goyvaerts, C., & Breckpot, K. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00113 · Cited by 81
“VEGF Monoclonal Ab Human (colon, lung, and breast cancer) ↓Immature DCs (105)”
BackgroundThe tumour microenvironment: a novel target for cancer therapy
Hanna, E., Quick, J. S., & Libutti, S. K. (2008) · Oral Diseases · doi:10.1111/j.1601-0825.2008.01471.x · Cited by 73
“Therefore, it has been postulated that blockade of VEGF may improve dendritic cell function, leading to enhanced anti-tumour immunity (Osada et al, 2008).”
BackgroundRadiation therapy and immunotherapy: Implications for a combined cancer treatment
Lévy, A., Chargari, C., Cheminant, M., Simon‐Tillaux, N., Bourgier, C., & Deutsch, É. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.09.001 · Cited by 73
Drug-eluting embolic microspheres: State-of-the-art and emerging clinical applications
Mikhail, A. S., Negussie, A. H., Mauda‐Havakuk, M., Owen, J., Pritchard, W. F., Lewis, A. L., & Wood, B. J. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1835858 · Cited by 73
“the immune effects caused by antiangiogenic agents are restoration of dendritic cell maturation, and reduction of T-regulatory cells [141,142].”
BackgroundAnti-Vascular Endothelial Growth Factor Therapy in Breast Cancer
Kristensen, T., Knutsson, M., Wehland, M., Laursen, B. E., Grimm, D. G., Warnke, E., & Magnusson, N. E. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151223024 · Cited by 70
Kreidieh, M., Mukherji, D., Temraz, S. N., & Shamseddine, A. I. (2020) · BioMed Research International · doi:10.1155/2020/9037217 · Cited by 80
Immune Effects of Bevacizumab: Killing Two Birds with One Stone
Elamin, Y. Y., Rafee, S., Toomey, S., & Hennessy, B. T. (2014) · Cancer Microenvironment · doi:10.1007/s12307-014-0160-8 · Cited by 68
Cancer Cells Exploit Notch Signaling to Redefine a Supportive Cytokine Milieu
Colombo, M., Mirandola, L., Chiriva‐Internati, M., Basile, A., Locati, M., Lesma, E. A., Chiaramonte, R., & Platonova, N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01823 · Cited by 71
Immunological off-target effects of standard treatments in gastrointestinal cancers
Duffy, A. G., & Greten, T. F. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt349 · Cited by 67
Improving cancer immunotherapy by targeting the STATe of MDSCs
de Haas, N., de Koning, C., Spilgies, L., de Vries, I. J. M., & Hato, S. V. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1196312 · Cited by 61
“VEGF antibody bevacizumab, reduced the frequency of immature myeloid cells in colorectal cancer patients.(53) Besides targeted cancer therapies, MDSC expansion can also be”
BackgroundCombined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer
Baraibar, I., Mirallas, O., Gonzalez, N. S., Ros, J., Salvà, F., Tabernero, J. M., & Élez, E. (2021) · Cancers · doi:10.3390/cancers13246311 · Cited by 67
Kravchenko, J. S., Corsini, E., Williams, M. A., Decker, W. K., Manjili, M. H., Otsuki, T., Singh, N., Al‐Mulla, F., Al-Temaimi, R. A., Amedei, A., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv033 · Cited by 63
Self-citation
Metadata
- Authors
- Osada, T., Chong, G., Tansik, R., Hong, T., Spector, N., Kumar, R., Hurwitz, H. I., Dev, I., Nixon, A. B., Lyerly, H. K., Clay, T., & Morse, M. A.
- Affiliations
- Duke Medical Center (US)
- GlaxoSmithKline (United Kingdom) (GB)
- Hartford Hospital (US)
- Corresponding author
- Morse, Michael A.
- ORCID
- Venue
- Cancer Immunology Immunotherapy
- Published
- 2008-01-10
- Volume
- 57
- Issue
- 8
- Pages
- 1115-1124
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC4110970
- OpenAlex
- W2067969350
- Cited by
- 311
- References
- 35
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 15 · 2023: 22 · 2022: 18 · 2021: 30 · 2020: 26 · 2019: 16 · 2018: 24 · 2017: 21 · 2016: 19 · 2015: 12 · 2014: 13 · 2013: 14 · 2012: 10
- FWCI
- 7.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- GlaxoSmithKline
- National Cancer Institute (K24CA113755, P01CA078673, 5 P01 CA78673.)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- anti-VEGF therapy, bevacizumab, dendritic cells, immature myeloid cells, DC2, dendritic cell maturation, vascular endothelial growth factor, angiogenesis, plasminogen activator inhibitor-1, urokinase, D-dimer, antitumor immunity, lung cancer, breast cancer, colorectal cancer, T cell proliferation
- MeSH terms
- Bevacizumab, Antibodies, Monoclonal, Breast Neoplasms, Cell Differentiation, Cells, Cultured, Dendritic Cells, Fibrin Fibrinogen Degradation Products, Humans, Immunotherapy, Lung Neoplasms, Neovascularization, Pathologic, Pilot Projects, T-Lymphocytes, Urokinase-Type Plasminogen Activator, Colorectal Neoplasms, Plasminogen Activator Inhibitor 1, Angiogenesis Inhibitors, Myeloid Progenitor Cells, Vascular Endothelial Growth Factor A, Cell Proliferation, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.